|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 257.65 CHF | -1.88% |
|
+0.23% | +0.82% |
| 05-15 | Foreign companies eye US expansion to lessen fallout from tariffs | RE |
| 05-15 | Roche: receives FDA approval for cancer drug | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last hours
Enjoy this offer
* See conditions on site
| Capitalization | 211B 255B 225B 190B 353B 21,868B 395B 2,443B 955B 9,916B 958B 938B 36,709B | P/E ratio 2025 * |
14.4x | P/E ratio 2026 * | 13.3x |
|---|---|---|---|---|---|
| Enterprise value | 222B 269B 237B 200B 372B 23,039B 416B 2,574B 1,007B 10,447B 1,010B 989B 38,674B | EV / Sales 2025 * |
3.52x | EV / Sales 2026 * | 3.29x |
| Free-Float |
87.84% | Yield 2025 * |
3.76% | Yield 2026 * | 3.86% |
More valuation ratios
* Estimated data
More news
Last Transcript: Roche Holding AG
More recommendations
More press releases
| 1 day | -0.61% | ||
| 1 week | +1.83% | ||
| Current month | -2.82% | ||
| 1 month | +2.71% | ||
| 3 months | -12.21% | ||
| 6 months | +2.91% | ||
| Current year | +2.43% |
| 1 week | 256.5 |  | 266.2 |
| 1 month | 246 | | 274.6 |
| Current year | 231.9 | | 313.8 |
| 1 year | 226.5 | | 313.8 |
| 3 years | 212.9 | | 335.85 |
| 5 years | 212.9 | | 404.2 |
| 10 years | 206.35 | | 404.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 14/03/2023 | |
Alan Hippe
DFI | Director of Finance/CFO | 58 | 05/06/2011 |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 58 | 09/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
André Hoffmann
BRD | Director/Board Member | 67 | 31/12/1995 |
Severin Schwan
CHM | Chairman | 58 | 14/03/2023 |
| Director/Board Member | 72 | 02/03/2015 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 9.03% | 121 M€ | -.--% | - | |
| 8.46% | 21 M€ | -1.14% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.59% | +1.83% | +12.85% | -19.35% | 255B | ||
| -2.95% | +1.31% | -9.74% | +142.58% | 651B | ||
| -0.31% | +4.66% | +1.28% | -13.45% | 369B | ||
| -1.65% | +2.46% | +11.58% | +20.39% | 321B | ||
| -2.23% | +2.73% | -51.65% | +18.72% | 308B | ||
| -0.40% | +3.44% | +0.31% | +6.58% | 223B | ||
| -0.27% | +3.19% | -15.32% | -1.26% | 219B | ||
| -1.27% | +4.78% | -41.13% | -17.71% | 193B | ||
| -1.33% | +3.45% | -13.82% | +9.63% | 146B | ||
| -1.27% | +9.49% | +60.08% | +68.73% | 134B | ||
| Average | -1.04% | +4.45% | -4.56% | +21.49% | 281.86B | |
| Weighted average by Cap. | -1.34% | +3.79% | -7.09% | +36.75% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 63.17B 76.54B 67.5B 56.94B 106B 6,551B 118B 732B 286B 2,971B 287B 281B 10,997B | 65.9B 79.85B 70.42B 59.4B 110B 6,834B 124B 763B 299B 3,099B 300B 293B 11,473B |
| Net income | 14.07B 17.05B 15.03B 12.68B 23.57B 1,459B 26.37B 163B 63.74B 662B 63.93B 62.61B 2,449B | 15.21B 18.43B 16.26B 13.71B 25.49B 1,578B 28.52B 176B 68.94B 715B 69.15B 67.71B 2,649B |
| Net Debt | 11.29B 13.68B 12.07B 10.18B 18.92B 1,171B 21.17B 131B 51.16B 531B 51.32B 50.25B 1,966B | 5.73B 6.95B 6.13B 5.17B 9.6B 594B 10.75B 66.41B 25.97B 270B 26.05B 25.51B 998B |
More financial data
* Estimated data
Employees
103,249
Sector
Pharmaceuticals
Calendar
05-27
- Investor Day
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/05/25 | 257.60 CHF | -1.90% | 200,257 |
| 21/05/25 | 262.60 CHF | -0.30% | 912,166 |
| 20/05/25 | 263.40 CHF | +1.31% | 944,876 |
| 19/05/25 | 260.00 CHF | +0.12% | 1,065,804 |
| 16/05/25 | 259.70 CHF | +1.05% | 1,706,043 |
Delayed Quote Swiss Exchange, May 22, 2025 at 08:12 am
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
262.60CHF
Average target price
302.63CHF
Spread / Average Target
+15.24%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition